News & Updates

The use of azole antifungal medications concurrently or sequentially with midostaurin is both safe and effective for patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukaemia (AML), reports a study.

A single-institution study has found a notably high incidence of chemotherapy-related adverse drug reactions (ADRs) in patients with multiple myeloma.

Three formulations of the 21-valent pneumococcal conjugate vaccine (PCV21) have shown favourable immunogenicity and acceptable tolerability profile among toddlers and infants, when compared with PCV13, in a phase II study.

Twice-daily application of ruxolitinib cream led to early and sustained improvement in the signs and symptoms of prurigo nodularis in adults, according to the pooled phase III TRuE-PN1 and TRuE-PN2 studies presented at EADV 2025.

In the treatment of patients with major depressive disorder (MDD), ammoxetine is well tolerated and shows superior efficacy relative to placebo, as shown in a phase II study conducted in China.

In the phase III C-POST trial, adjuvant cemiplimab prolongs disease-free survival (DFS) in individuals at high risk for recurrence of cutaneous squamous cell carcinoma (cSCC).

The investigational oral antiviral ensitrelvir shows potent antiviral activity in COVID-19, although its effect is slightly weaker than that of ritonavir-boosted nirmatrelvir, according to the ongoing, phase II, randomized controlled, adaptive pharmacometric platform PLATCOV trial.